In the claims:

1. (Currently amended) A method for the inhalation of a dry powder drug, the method comprising:

providing a dry powder drug composition comprising particles comprising a lipid matrix and a particle size of 1-30 microns, mass median aerodynamic diameter of less than 5 microns, and bulk density of less than 0.5 g/cm$^3$;

loading the composition into a passive dry powder inhaler having a resistance of from 0.01 to 0.30 $(cmH_2O)^{1/2}/Lmin^{-1}$; and

inhaling the drug composition from the inhaler,

wherein the emitted dose is at least 60% for flow rates from 10 to 60 liters per minute ~~resulting in an emitted dose substantially independent of device resistance and lung deposition substantially independent of inhalation flow rate~~.

2. (Cancelled)

3. (Currently amended) A method according to claim 2 wherein the ~~comprising an~~ emitted dose is ~~of~~ at least 80% for flow rates from 10 to 60 liters per minute.

4. (Currently amended) A method according to claim 1 wherein the fine particle fraction is ~~comprising a $FPF_{4\mu}$ of~~ at least 60%.

5. (Original) A method according to claim 1 wherein the lipid comprises a phospholipid selected from the group consisting of dipalmitoylphosphatidylcholine, disteroylphosphatidylcholine, diarachidoylphosphatidylcholine dibehenoylphosphatidylcholine, diphosphatidyl glycerol, short-chain phosphatidylcholines, long-chain saturated phosphatidylethanolamines, long-chain saturated phosphatidylserines, long-chain saturated phosphatidylglycerols, and long-chain saturated phosphatidylinositols.

6-10. (Cancelled)

11. (Currently amended) A method according to ~~of~~ claim 1 wherein the lung deposition is greater than 25%.

12. (Original) A method according to claim 1 wherein the lung deposition is greater than 30%.

13. (Original) A method according to claim 1 wherein the lung deposition is greater than 50%.

14. (Original) A method according to claim 1 wherein the drug is selected from the group consisting of budesonide, tobramycin sulfate, leuprolide acetate, Amphotericin B, and PTH.

15. (Currently amended) A method according to ~~of~~ claim 1 wherein the powder comprises hollow porous microparticles.

16-20. (Cancelled)